Gynecologic Oncology Reports最新文献

{"title":"Immunotherapy challenges surgical dogma in placental site trophoblastic tumor","authors":"J. Michael Straughn Jr., Teresa K.L Boitano","doi":"10.1016/j.gore.2026.102076","DOIUrl":"10.1016/j.gore.2026.102076","url":null,"abstract":"","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"64 ","pages":"Article 102076"},"PeriodicalIF":1.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147709416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disparities in not recommending chemotherapy for individuals with newly diagnosed advanced endometrial cancer due to “patient risk factors”","authors":"Xuan Li ,&nbsp;Allison Dona ,&nbsp;Sarah Boyle ,&nbsp;Katherine Cooke ,&nbsp;Deanna Teoh ,&nbsp;Rachel I. Vogel","doi":"10.1016/j.gore.2026.102072","DOIUrl":"10.1016/j.gore.2026.102072","url":null,"abstract":"<div><h3>Objectives</h3><div>We sought to identify patient sociodemographic characteristics associated with not recommending chemotherapy due to “patient risk factors” for individuals diagnosed with advanced-stage endometrial cancer. Methods: We conducted a retrospective analysis of individuals newly diagnosed with stage III or IV endometrial cancer between 2004–2021 utilizing the National Cancer Database (NCDB). The primary outcome was indication that “chemotherapy was not recommended/administered because it was contraindicated due to patient risk factors (i.e., comorbid conditions, advanced age […])” compared to chemotherapy recommended, regardless of administration. A logistic regression model examined associations between patient sociodemographic characteristics (age, race, ethnicity, education, type of insurance, urban/rural residence) and not recommending chemotherapy due to patient risk factors, adjusting for clinical factors including Charlson-Deyo comorbidity index scores, stage, histology, grade, and facility type.</div></div><div><h3>Results</h3><div>Among the 96,497 individuals included in the analysis, chemotherapy was not recommended for 2,030 (2.1%) due to “patient risk factors.” Increasing age, Black race, living in a zip code with lower rates of high school completion, and having no insurance or government insurance were independently associated with chemotherapy not being recommended after adjusting for clinical variables. Sensitivity analyses excluding subgroups more likely to have clinical contraindications, including those who did not have surgery, had a Charlson-Deyo comorbidity index score &gt; 0, or died within 30 days of surgery found similar results.</div></div><div><h3>Conclusions</h3><div>Despite National Comprehensive Cancer Network guidelines recommending chemotherapy for frontline treatment of advanced-stage endometrial cancer, disparities in recommendations for chemotherapy were observed by sociodemographic factors including race, age, education, and insurance status.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"64 ","pages":"Article 102072"},"PeriodicalIF":1.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147656372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Internal hemipelvectomy with left hip transposition of a recurrent non − specific molecular profile synchronous endometrial endometrioid and ovarian endometrioid cancer","authors":"Jamie Roslyn T. Young ,&nbsp;Czar Louie Gaston ,&nbsp;Renee Vina G. Sicam","doi":"10.1016/j.gore.2026.102073","DOIUrl":"10.1016/j.gore.2026.102073","url":null,"abstract":"<div><h3>Background</h3><div>Synchronous endometrial and ovarian carcinoma (SEOC) usually affects young, premenopausal, and nulliparous individuals. Despite its relatively good clinical outcome, SEOCs may recur depending on the patient’s risk factors. While several reports describe primary cases of SEOC, the management of recurrent disease has not been defined.</div></div><div><h3>Case presentation</h3><div>The authors report a case of a 38-year-old, nulligravid, who was diagnosed with a synchronous endometrial endometrioid and ovarian endometrioid carcinoma. She had local recurrences on the left pelvic region occurring at three-year intervals and was managed surgically. During the most recent tumor recurrence, the patient underwent an internal hemipelvectomy with left hip transposition for complete tumor resection. This complex procedure required a multidisciplinary team. The mass was sent for molecular analysis showing a non − specific molecular profile (NSMP). Postoperative adjuvant radiotherapy was discussed with the patient in a multidisciplinary setting. Given that clear surgical margins were achieved, the patient opted to forgo radiotherapy to avoid potential complications. The patient is on close surveillance and remains disease free four months from surgery. Currently, she has progressed to full weightbearing from an initial period of being wheelchair bound.</div></div><div><h3>Conclusion</h3><div>This case highlights the behavior of NSMP endometrial tumors, specifically SEOCs. It also illustrates that localized recurrences of SEOCs could be treated aggressively with complete surgical resection. Given the complexity of these procedures, successful outcomes depend on a carefully coordinated operative plan developed by a multidisciplinary team of specialists.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"64 ","pages":"Article 102073"},"PeriodicalIF":1.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147656375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Surgical debulking with fertility preservation in primary extra-neural ependymoma presenting with widespread peritoneal and intra-abdominal disease: Case report and literature review","authors":"Danielle Christmas ,&nbsp;Harrison Odgers ,&nbsp;Georgina Elton ,&nbsp;Katrina Tang ,&nbsp;Christine Kang ,&nbsp;King Man Wan","doi":"10.1016/j.gore.2026.102071","DOIUrl":"10.1016/j.gore.2026.102071","url":null,"abstract":"<div><h3>Background</h3><div>Extra-neural ependymoma is an extremely rare neoplasm with reported cases arising from the ovary, pelvis, broad and uterosacral ligaments, peritoneum and mediastinum.</div></div><div><h3>Case Presentation</h3><div>A 29-year-old woman presented with abdominal pain. Computed tomography demonstrated bilateral adnexal masses, omental and peritoneal nodules and a 140 mm left upper quadrant mass. FDG PET/CT showed avid, disseminated abdominal disease. CA125 was 265. Differential diagnoses included tubo-ovarian malignancy, peritoneal carcinomatosis, and mesenchymal tumours. Diagnostic laparoscopy with biopsy established Stage IV extra-neural ependymoma based on histological features, immunophenotype and the absence of central nervous system disease on magnetic resonance imaging. She underwent primary cytoreduction including en bloc hysterectomy with ultra-low anterior resection, right salpingoophorectomy, left salpingectomy, peritonectomy, splenectomy with en-bloc partial resection of the left hemi-diaphragm and loop ileostomy. Intraoperatively, the right ovary was utilised for ex-vivo in-vitro oocyte maturation, and the left ovary was conserved for oocyte retrieval and cryopreservation for future surrogacy. Adjuvant chemotherapy was recommended but declined. She remained well at eleven months post-operatively.</div></div><div><h3>Conclusion</h3><div>Extra-neural ependymomas are exceedingly rare with five reported cases of peritoneal ependymoma. Extra-neural ependymomas demonstrate distinct histological and immunophenotypic profiles including increased architectural variability within the spindled cell perivascular pseudorosettes characteristic of ependymomas and diffuse ER and PR positivity. Given limited evidence, optimal management remains undefined however surgical cytoreduction continues to be the cornerstone of management across reported cases with adjuvant treatment individualised. Certain fertility preservation strategies are concurrently feasible within a multidisciplinary framework and should be considered given reported cases are predominantly seen in younger females.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"64 ","pages":"Article 102071"},"PeriodicalIF":1.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147656380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Active surveillance of an endometriosis-related, hormone-responsive pelvic adenosarcoma during pregnancy: A case report","authors":"Amar Zaidan ,&nbsp;Kelly H Bruce ,&nbsp;Mark R Hopkins ,&nbsp;Steven I Robinson ,&nbsp;Carl H Rose ,&nbsp;Wendaline M VanBuren ,&nbsp;Carrie L Langstraat","doi":"10.1016/j.gore.2026.102029","DOIUrl":"10.1016/j.gore.2026.102029","url":null,"abstract":"<div><h3>Background</h3><div>Extrauterine adenosarcomas are rare gynecologic malignancies that can arise within foci of pelvic endometriosis. They are often hormone mediated and thus are challenging to treat during pregnancy.</div></div><div><h3>Case presentation</h3><div>We present the case of a hormone-receptor positive extrauterine adenosarcoma arising within a known focus of pelvic endometriosis diagnosed in the second trimester of pregnancy. The posterior pelvic mass involved and completely obstructed the colon. The patient desired pregnancy continuation and was managed with surgical intestinal diversion followed by serial surveillance with MRI imaging. Indicated primary preterm cesarean delivery was performed at 30 weeks gestation, after which she was treated with dual anti-estrogen therapy followed by definitive surgical resection. Fifteen months after surgery, she remains free from disease.</div></div><div><h3>Conclusion</h3><div>We review salient topics including malignant transformation of endometriosis, hormone therapy for adenosarcoma without sarcomatous overgrowth, and ethical considerations of cancer management during pregnancy.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"63 ","pages":"Article 102029"},"PeriodicalIF":1.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145921638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The use of ultrasound guidance for endometrial sampling in patient populations with known or suspected cervical stenosis: A retrospective case review","authors":"Courtney Nail ,&nbsp;Sara Moufarrij ,&nbsp;Jennifer J. Mueller ,&nbsp;Mario M. Leitao Jr. ,&nbsp;Nadeem R. Abu-Rustum ,&nbsp;Dennis S. Chi ,&nbsp;Duan Li","doi":"10.1016/j.gore.2026.102030","DOIUrl":"10.1016/j.gore.2026.102030","url":null,"abstract":"<div><h3>Objective</h3><div>To assess the safety, efficacy, and diagnostic adequacy of ultrasound-guided endometrial sampling (UGES) in patients with known or suspected cervical stenosis.</div></div><div><h3>Methods</h3><div>We reviewed records of patients who underwent UGES (under general anesthesia) due to cervical stenosis at our center between 1999 and 2024. Of 181 patients identified, 155 were included. Key outcomes included success rate, complication rates, and histopathological findings.</div></div><div><h3>Results</h3><div>The most common indications for sampling included postmenopausal bleeding (72 of 155, 46.5%), abnormal imaging findings (40 of 155, 25.8%), abnormal Papanicolaou test (16 of 155, 10.3%), and neocervix creation after treatment for cervical cancer (10 of 155, 6.5%). The overall success rate of UGES in gaining access to the endometrial canal for assessment of underlying pathology was 93.5% (145 of 155). Of 155 patients, 150 underwent UGES for histopathologic diagnosis; 131 (84.5%) provided adequate tissue for pathologic analysis, 15 (10%) had a sample obtained but had insufficient tissue for pathologic analysis, and 4 (2.7%) failed to provide a tissue sample due to inability to access the endometrial cavity. Overall, 109 of 155 samples (70.3%) were benign and 18 (11.6%) were malignant. All 5 procedures performed for therapeutic reasons were successful. Seven patients (4.5%) experienced a minor adverse event from UGES. No major complications occurred.</div></div><div><h3>Conclusion(s)</h3><div>UGES appears to be an effective and safe technique for patients with cervical stenosis. We observed a low complication rate and a high diagnostic yield, suggesting UGES may be a valuable alternative for endometrial evaluation in this challenging setting.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"63 ","pages":"Article 102030"},"PeriodicalIF":1.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146170266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Temporary intraperitoneal breast implant spacer to facilitate safe stereotactic body radiotherapy for recurrent high-grade serous ovarian carcinoma","authors":"Caleigh E. Smith ,&nbsp;Emilie K. Sandfeld ,&nbsp;Sheen Cherian ,&nbsp;Peter G. Rose","doi":"10.1016/j.gore.2026.102040","DOIUrl":"10.1016/j.gore.2026.102040","url":null,"abstract":"<div><h3>Background</h3><div>Recurrent ovarian cancer involving the upper abdomen can be challenging to treat with radiation therapy due to the proximity of bowel. Spacer technologies have been used in other malignancies to displace radiosensitive organs, but they are not routinely employed in gynecologic oncology.</div></div><div><h3>Case</h3><div>We report the case of a 71-year-old woman with a germline BRCA1 mutation and recurrent high-grade serous carcinoma following secondary cytoreduction with right hepatectomy and diaphragmatic resection. Surveillance imaging demonstrated a right upper quadrant abdominal wall recurrence overlying the hepatic flexure, precluding safe stereotactic body radiation therapy (SBRT). Following multidisciplinary review, the patient underwent an exploratory laparotomy with adhesiolysis and placement of a saline-filled breast implant in the right upper quadrant to exclude bowel from the radiation field. Postoperative CT confirmed displacement of the colon, and the patient subsequently received one fraction of SBRT to the abdominal wall. The implant was removed uneventfully two days later. The patient recovered well, and subsequent imaging two months later showed the desired reduction in RUQ disease.</div></div><div><h3>Conclusion</h3><div>This is the first report, to our knowledge, of the use of a breast implant as a temporary spacer to facilitate safe SBRT in recurrent ovarian cancer. This removable, cost-effective approach offers a feasible solution for anatomically constrained upper abdominal recurrences in close proximity to the bowel.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"63 ","pages":"Article 102040"},"PeriodicalIF":1.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146073631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rising U.S. trends in HPV-positive and HPV-negative vulvar cancer in older adults, 2000–2020","authors":"Ana Paola Mata Zetina ,&nbsp;Sritha Rajupet ,&nbsp;Theodore Strange ,&nbsp;Adi Davidov ,&nbsp;Meekoo Dhar ,&nbsp;Lohitha Dhulipalla ,&nbsp;Thomas Gut ,&nbsp;Kathleen H. Scarbrough ,&nbsp;Mario R. Castellanos","doi":"10.1016/j.gore.2025.102016","DOIUrl":"10.1016/j.gore.2025.102016","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate rising vulvar cancer incidence in the United States, particularly in individuals aged ≥55, and assess whether increases are driven by HPV-positive or HPV-negative disease.</div></div><div><h3>Methods</h3><div>We analyzed vulvar cancer incidence trends from 2000 to 2020 using data from the National Cancer Institute’s SEER program, covering 47.9 % of the U.S. population. Cases were classified as HPV-positive or HPV-negative, and age groups were stratified as &lt;55, 55–64, and 65 + . Linear regression analyses assessed trends and racial/ethnic disparities, with statistical significance set at p &lt; 0.05.</div></div><div><h3>Results</h3><div>Vulvar cancer incidence increased significantly among individuals aged ≥55 from 2000 to 2020 (p &lt; 0.01), with both HPV-positive and HPV-negative cases contributing to this rise. The sharpest increase in HPV-positive cancers occurred in the 55–64 age group, with a 53 % increase, while HPV-negative cancers in this same group rose by 23 %. Individuals aged ≥65 also experienced increases in both subtypes, though to a lesser extent. In contrast, individuals under 55 slightly declined in HPV-positive (1.5 %) and HPV-negative (5 %) cases over the same period.</div></div><div><h3>Conclusion</h3><div>The rising incidence of both HPV-positive and HPV-negative vulvar cancer among individuals aged ≥55 reflects shifting trends in disease burden. These findings align with prior SEER analyses showing an in situ diagnoses decline and a rise in invasive cases. In the absence of standardized screening guidelines for vulvar cancer, our results underscore the importance of continued surveillance and risk-based gynecologic evaluation strategies in older populations.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"63 ","pages":"Article 102016"},"PeriodicalIF":1.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145972991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Invasive Acantholytic Extramammary Paget's Disease of the Vulva With Mammary Carcinoma-Like Differentiation and MMR Loss: Report of an Unusual Case and Its Clinical Mimics","authors":"Jessica Claus ,&nbsp;Janina Pearce ,&nbsp;Areta Bojko ,&nbsp;Padmini Manrai ,&nbsp;M.Ruhul Quddus ,&nbsp;Shivali Marketkar","doi":"10.1016/j.gore.2025.102007","DOIUrl":"10.1016/j.gore.2025.102007","url":null,"abstract":"<div><h3>Background</h3><div>Paget’s disease (EMPD) of the vulva primarily affects postmenopausal women and can present significant challenges in early clinical detection.</div><div><strong>Case Presentation:</strong> We report an exceedingly rare case of invasive acantholytic extramammary Paget’s disease in a 78-year-old female patient. After biopsy-proven carcinoma, a radical hemivulvectomy of the left vulva was performed, which revealed an invasive adenocarcinoma, most consistent with primary extramammary Paget’s carcinoma. Histologic examination demonstrated a unique morphology, featuring an in-situ component with suprabasal intraepidermal acantholysis and an invasive component with various morphologies, including basaloid, skin adnexal-like, focal squamoid, and mammary-like differentiation, resembling ductal carcinoma in situ (DCIS) with comedonecrosis and invasive ductal carcinoma. This varied morphology has not been described before. Interestingly, the tumor shows loss of MMR protein (MSH2, MSH6).</div></div><div><h3>Conclusion</h3><div>In the literature, acantholytic Paget’s disease and acantholytic anaplastic Paget’s disease have been used interchangeably. While anaplastic Paget’s disease has been reported in the mammary and extramammary sites (scrotum, esophagus), involvement of the vulva has been reported only once in the literature. However, the current case is the first documented loss of MMR. Both cases presented with invasive disease ranging in depth from 3-5 mm, and positive lymph nodes emphasizing on the urgent need to further explore prognostic factors of this rare entity and to differentiate it from other acantholytic lesions, such as squamous cell carcinoma in situ and other acantholytic dermatoses.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"63 ","pages":"Article 102007"},"PeriodicalIF":1.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145921635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proton beam therapy as an effective treatment option for recurrent endometrial cancer","authors":"Yuta Endo ,&nbsp;Yoshiaki Takagawa ,&nbsp;Yuki Yoshimoto ,&nbsp;Koki Ando ,&nbsp;Rei Nishikawa ,&nbsp;Masanori Machida ,&nbsp;Yuntao Dai ,&nbsp;Ichiro Seto ,&nbsp;Motohisa Suzuki ,&nbsp;Takahiro Kato ,&nbsp;Shigenori Furukawa ,&nbsp;Shu Soeda ,&nbsp;Keiya Fujimori ,&nbsp;Masao Murakami","doi":"10.1016/j.gore.2025.102009","DOIUrl":"10.1016/j.gore.2025.102009","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the efficacy and safety of proton beam therapy (PBT) for recurrent endometrial cancer (REC) and to identify predictors of local control (LC).</div></div><div><h3>Methods</h3><div>We retrospectively reviewed REC patients treated with PBT at our institution between 2008 and 2021. LC, progression-free survival (PFS), and overall survival (OS) were estimated using the Kaplan–Meier method, and prognostic factors were analyzed. Toxicities were graded according to CTCAE v5.0.</div></div><div><h3>Results</h3><div>Nine patients with a total of 14 lesions were included (median follow-up, 36.4 months). The 1- and 2-year LC rates were 80.2 % and 68.8 %, respectively. Median PFS and OS were 13.6 and 36.4 months, respectively. Tumor size significantly influenced LC, with lesions &lt; 22.5 mm showing superior outcomes. No grade ≥ 3 toxicities attributable to PBT were observed.</div></div><div><h3>Conclusions</h3><div>These findings suggest that PBT may be a safe and effective salvage treatment for REC, particularly in patients with smaller tumors.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"63 ","pages":"Article 102009"},"PeriodicalIF":1.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145921587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}